Our current portfolio of investigational product candidates, AL101 and AL102, targets aberrant activation of the Notch-pathway with gamma secretase inhibitors.
When gamma secretase, the enzyme responsible for Notch activation, is inhibited, it turns off the Notch-pathway activation. Aberrant activation of the Notch-pathway has long been implicated in multiple solid tumor and hematological cancers and has often been associated with more aggressive cancers. Notch serves as a critical facilitator in processes, such as cellular proliferation, survival, migration, invasion, drug resistance and metastatic spread - all of which contribute to poorer patient prognosis.
AL101 and AL102 are designed to address the underlying key drivers of tumor growth by targeting Notch-pathway activation directly.
We’re working on therapies that, if approved by regulatory authorities, could transform today’s treatment options for people living with rare tumors and aggressive cancers.